Agenus shared a post on LinkedIn:
“Agenus announces four abstracts at ASCO 2026, including the first Phase 2 presentation of botensilimab ± balstilimab in advanced cutaneous melanoma, along with colorectal cancer and translational research updates.
We look forward to sharing progress across the BOT+BAL Immunotherapy program as we advance new approaches for patients with high unmet need.
Read the full release for details.”
Other articles from Agenus on OncoDaily.